Use of polypeptides in combating addiction and relapse and complexes and polypeptides - Patents.com
A polypeptide targeting the D2R/NR2B interaction effectively treats addiction and prevents relapse by inhibiting addictive behaviors and memories, addressing the limitations of current treatments.
Patent Information
- Application Number
- JP2024527302
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-09
- Filing Date
- 2022-09-06
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-09-06
AI Technical Summary
Current treatments for substance addiction, such as opioid and alcohol dependence, are inadequate in reducing psychological dependence and preventing relapse, despite some effectiveness in managing physical withdrawal symptoms.
A polypeptide that disrupts the interaction between D2 receptors and NMDA receptors, specifically targeting the D2R/NR2B complex, is used to treat addiction and prevent relapse by inhibiting the formation of addictive behaviors and memories.
The polypeptide effectively reduces the frequency and severity of addictive behaviors and prevents relapse, even under varying doses and stress conditions, demonstrating statistically significant clinical potential.
Smart Images

Figure 2024544512000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of substance addiction, and in particular to the use of polypeptides in the prevention or treatment of addiction or relapse thereto. [Background technology]
[0002] Substance addiction is defined by the World Health Organization (WHO) as repeated use of a substance despite awareness and previous experience of its harmful effects. Substance addiction is a chronic, relapsing disorder characterized by uncontrollable substance use, compulsive seeking and craving for the substance, continued use despite harmful effects, and physical and / or psychological dependence on the substance. In general, substance addiction follows a progression of tolerance, withdrawal, compulsive drug-using behavior, drug-seeking behavior, addictive behavior, and relapse.
[0003] Substance addiction has become a global medical and social problem, with a large social and economic impact on both addicts and society. For example, substance addiction is often closely associated with violent crime and the spread of infectious diseases. As another example, substance addiction can cause addicts to lose all or part of their workforce, which has a negative impact on individuals, families, and society. In particular, as one of the most commonly abused substances in the world, alcoholism can cause serious liver and cardiovascular diseases, and can lead to serious mental disorders and social problems, as well as family breakdown, tragic accidents, and reduced work efficiency.
[0004] Although several withdrawal medications are often used in drug detoxification or withdrawal treatment for addicted individuals, these medications still have limitations.
[0005] For example, common methods used in cases of opioid addiction include (i) substitution therapy (currently, substitution with methadone is most commonly used for drug detoxification); (ii) opioid receptor antagonists naltrexone or naloxone to facilitate withdrawal; and (c) non-opioid treatments using clonidine and lofexidine to suppress withdrawal symptoms. Although these methods can prevent the addict from experiencing physical discomfort (chills, vomiting, tremors, etc.) after the addict stops using the addictive substance, studies have shown that these medicines do not reduce the addict's psychological dependence (or psychological dependency).
[0006] As another example, the potential therapeutic effects of various types of medicines (such as naltrexone, acamprosate, ondansetron, disulfiram, gamma-hydroxybutyric acid (GHB), and topiramate) on alcohol addiction are being tested. Among these therapeutic medicines, naltrexone, acamprosate, and disulfiram have been confirmed to have certain effects and are approved for the treatment of alcoholism. Also, among these medicines, naltrexone is currently considered to be a good pharmacological option. However, although these medicines (including naltrexone) have shown some promising results, they are not sufficiently effective against alcoholism, and the prognosis remains poor.
[0007] Therefore, there is a strong need in the field of substance addiction treatment to develop safe and effective pharmaceutical agents to provide a greater variety of better treatment or prevention strategies for substance addiction and its relapse. Summary of the Invention [Means for solving the problem]
[0008] To achieve the above object, the present inventors have conducted numerous studies on the molecular mechanisms of addiction and found that a new polypeptide can disrupt the interaction between D2 receptors and NMDA receptors.
[0009] Specifically, dopamine (DA) receptors are a type of receptor present in living organisms, and exert their effects via corresponding cell membrane receptors. DA receptors can be classified into five types: D1, D2, D3, D4, and D5. D2 receptors (D2R) are widely expressed in the brain.
[0010] NMDA receptors (NMDARs) play important physiological roles in the development of the nervous system, such as controlling the survival of neurons, controlling the development of neuronal dendrites and axons, and participating in the formation of synaptic plasticity, as well as in the formation of neural circuits and the pathogenesis of various neuropsychiatric disorders. Data show that NMDA receptors are one of the most important receptors in learning and memory processes. NMDARs are composed of three main subunits, NR1, NR2, and NR3, and the NR2 subunit has four subunits, NR2A, NR2B, NR2C, and NR2D.
[0011] The present inventors have confirmed that the polypeptide of the present invention is effective in treating addiction to an addictive substance and in preventing or treating relapse, and have completed the present invention.
[0012] Thus, in a first aspect, the present invention provides a polypeptide consisting of at least 11 consecutive amino acid residues of the sequence shown in SEQ ID NO: 1 and comprising the sequence shown in SEQ ID NO: 2. The present invention also provides the use of a polypeptide of the invention in the preparation of a medicament for the prevention and / or treatment of substance addiction.
[0013] As used herein, "treatment" refers to producing a desired or beneficial effect in a patient, and may include reducing the frequency or severity of one or more symptoms of a disease, or inhibiting or preventing further onset of a disease, condition, or disorder.
[0014] As used herein, "prevention" means preventing or delaying the onset of a disease, or preventing the onset of its clinical or subclinical symptoms.
[0015] As used herein, "substance addiction" refers to a chronic, relapsing disorder characterized by uncontrollable substance use, compulsive seeking and craving for the substance, persistent use despite harmful effects, and physical and / or psychological dependence on the substance. Substance addiction may be, for example, an addiction that occurs upon initial use of the substance, or may refer to the formation of a substance addiction and / or the manifestation of a substance addiction.
[0016] In an exemplary embodiment, a polypeptide of the invention consists of at least 11 contiguous amino acid residues, at least 12 contiguous amino acid residues, at least 13 contiguous amino acid residues, at least 14 contiguous amino acid residues, or at least 15 contiguous amino acid residues of the sequence set forth in SEQ ID NO:1.
[0017] In an exemplary embodiment, the sequence of the polypeptide of the present invention consists of positions 1 to 15, 1 to 14, 1 to 13, 2 to 15, 2 to 14, 2 to 13, 3 to 15, 3 to 14, or 3 to 13 of SEQ ID NO: 1 (KIYIVLRRRRKRVNT).
[0018] In a specific embodiment, the sequence of a polypeptide of the invention is shown in SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:4.
[0019] In some embodiments, the addictive substance may be selected from the group consisting of, for example, morphine, nicotine, alcohol, cocaine, codeine, dihydrocodeine, hydromorphone, oxycodone, methadone, morphine, fentanyl, and pethidine.
[0020] In a second aspect, the present invention provides the use of a polypeptide of the invention in the preparation of a medicament for the prevention and / or treatment of relapse to a substance addiction.
[0021] As used herein, "relapse", also known in some contexts as "drug relapse", refers to an addict's return to use of a previously used addictive substance after withdrawal. Relapse can be triggered by environmental factors (events), addictive substance factors, and / or stressors (stress).
[0022] In an exemplary embodiment, the recurrence according to the present invention is caused by an environmental factor.
[0023] In an exemplary embodiment, relapse in accordance with the present invention is caused by an addictive substance trigger.
[0024] In an exemplary embodiment, a relapse according to the present invention is caused by a stressor.
[0025] The inventors have unexpectedly discovered that the polypeptides of the invention are capable of inhibiting the binding that results in the formation of the D2R / NR2B complex, thereby eliminating the formation of addictive substances.
[0026] Furthermore, the polypeptide of the present invention can eliminate relapse to addiction caused by environmental factors, addictive substance factors, and stress factors, and exerts statistically significant effects even under conditions induced by high / low doses of addictive substances, making it highly worthy of clinical development.
[0027] In a third aspect, the present invention provides a nucleic acid molecule encoding a polypeptide of the present invention.Furthermore, the present invention provides the use of a nucleic acid molecule of the present invention in the preparation of a medicament for the treatment and / or prevention of a substance addiction, or the use of a nucleic acid molecule of the present invention in the preparation of a medicament for the treatment and / or prevention of relapse to a substance addiction.
[0028] The polypeptide of the present invention is produced using the nucleic acid molecule of the present invention, and the sequence of the nucleic acid molecule of the present invention can be appropriately adjusted by those skilled in the art depending on the expression system used.
[0029] In an exemplary embodiment, the nucleic acid molecule has the sequence shown in SEQ ID NO:5.
[0030] In a fourth aspect, the present invention provides an expression vector comprising a nucleic acid molecule of the present invention.Furthermore, the present invention provides the use of an expression vector of the present invention in the preparation of a medicament for the treatment and / or prevention of a substance addiction, or the use of an expression vector of the present invention in the preparation of a medicament for the treatment and / or prevention of relapse to a substance addiction.
[0031] The nucleic acid sequence of the present invention can be inserted into expression vector by using various known methods.For example, the nucleic acid molecule of the present invention can be inserted into suitable restriction endonuclease site.In addition, the standard techniques of cloning, isolation, amplification and purification, enzyme reaction using DNA ligase, DNA polymerase or restriction endonuclease, and various separation techniques during operation belong to the commonly used techniques known to those skilled in the art.
[0032] In a fifth aspect, the present invention provides a host cell comprising a nucleic acid molecule or an expression vector of the present invention.Furthermore, the present invention provides the use of the host cell of the present invention in the preparation of a medicament for the treatment and / or prevention of a substance addiction, or the use of the host cell of the present invention in the preparation of a medicament for the treatment and / or prevention of relapse to a substance addiction.
[0033] The polypeptide of the present invention may be produced using an expression vector and a host cell in various expression systems, such as a prokaryotic expression system or a eukaryotic expression system. An example of a mammalian expression system is described below. The host cell may include monkey kidney fibroblast COS-7 cell line, and other cell lines capable of expressing a compatible vector, such as C127 cell line, 3T3 cell line, CHO cell line, Hela cell line, BHK cell line, etc. Mammalian expression vectors must contain an origin of replication, a suitable promoter and enhancer, and, if necessary, a ribosome binding site, a polyadenylation site, splicing donor and acceptor sites, a transcription termination sequence, and a 5' flanking non-transcribed sequence. For example, DNA sequences derived from the SV40 splice and polyadenylation sites, respectively, may be used to provide the desired non-transcribed genetic elements. The expression vector may be introduced into the host cell by various methods well known to those skilled in the art, including, but not limited to, calcium phosphate transfection, DEAE-glucan-based transfection, or electroporation.
[0034] In a sixth aspect, the present invention provides a complex comprising a polypeptide of the present invention and a (transport) carrier bound to said polypeptide for penetrating the blood-brain barrier.
[0035] In an exemplary embodiment, the carrier used to penetrate the blood-brain barrier is HIV-1 Tat protein, insulin, cationized albumin, a monoclonal antibody against the rat transferrin receptor (OX26), a mouse-derived monoclonal antibody against the human insulin receptor (HIRMAb), Penetratin, the transduction domain of the Tat protein, Pep-1 peptide, S4 13-PV, Magainin 2 and Buforin 2. For example, the transduction domain of TAT, the amino acids of which are YGRKKRRQRRR (shown in SEQ ID NO: 6), can transduce across the cell membrane into the cell.
[0036] The polypeptide of the present invention can be linked to a carrier for penetrating the blood-brain barrier by a suitable linking technique. Exemplary linking techniques may be avidin-biotin technique, spacer arm technique using polyethylene glycol (PEG), fusion protein technique, etc. For example, when the transduction domain of HIV-1 Tat protein is used as a carrier for penetrating the blood-brain barrier, the polypeptide of the present invention can be directly linked to the transduction domain of Tat protein by fusion protein technique.
[0037] In some embodiments, when using fusion protein technology, the polypeptide of the present invention can be linked to a carrier for penetrating the blood-brain barrier using a linker. Exemplary linkers can be flexible linkers containing glycine, such as G, GSG, GSGGSG, GSGGSGG, GSGGSGGG, GGGGSGGG, GGGGS, SGG, etc.
[0038] In a seventh aspect, the present invention provides a method of treating or preventing a substance addiction in a subject, comprising: The method includes administering to a subject an effective amount of a polypeptide or complex of the invention.
[0039] The present invention further provides a method for preventing relapse to a substance addiction in a subject, comprising: The method includes administering to a subject an effective amount of a polypeptide or complex of the invention.
[0040] The polypeptides or complexes of the invention achieve this method by decreasing the interaction between D2R and NR2B.
[0041] "Effective amount" or "therapeutically effective amount" refers to an amount of active agent sufficient to induce a desired biological result. The desired biological result may be a reduction in the signs, symptoms or causes of a disease, or other desired changes in a biological system. In this specification, the term "therapeutically effective amount" is used to mean an amount of a formulation that can substantially improve the condition of a disease when administered repeatedly to the affected area for a certain period of time. The therapeutically effective amount varies depending on the condition to be treated, the progression of the condition, and the type and concentration of the formulation used. Those skilled in the art will be able to determine the appropriate amount by performing routine experimentation.
[0042] The terms "subject", "individual" or "patient" are used interchangeably herein and refer to vertebrates, preferably mammals, and more preferably humans. Mammals include, but are not limited to, rats, monkeys, humans, livestock and pets. Also included are biological tissues and cells obtained or cultured in vitro and the progeny thereof.
[0043] In an eighth aspect, the present invention provides a polypeptide or complex of the invention for use as a medicament.
[0044] In some embodiments, medicinal use refers to use to treat or prevent substance addiction.
[0045] In some embodiments, medicinal use refers to use to prevent relapse of a substance addiction. [Brief description of the drawings]
[0046] [Figure 1] Shown are the results of co-immunoprecipitation of hippocampal tissue from mice. [Diagram 2] The position on D2R of each fragment used in Example 3 is shown. [Diagram 3] 1 shows the results of a GST pull-down experiment for each fragment of Example 3. [Figure 4] 1 shows the results of co-immunoprecipitation of hippocampal tissue from place-preference (CPP) and behaviorally sensitized (BS) mice treated with KT polypeptide. [Diagram 5] 1 shows the experimental scheme design of Example 5. [Figure 6] 1 shows the results of CPP scores in Example 5. [Figure 7] 1 shows the experimental scheme design of Example 6. [Figure 8] 1 shows the results of CPP scores in Example 6. A: Measurement results for each group on day 10; B: Comparison of results for the TAT-D2R-KT group on days 10 and 11. [Figure 9] 1 shows the design of the experimental scheme of Example 7. [Figure 10] 1 shows the results of CPP measurement on the 10th day in Example 7. [Figure 11] 1 shows the results of CPP measurement in Test 1 of Example 7. [Figure 12] 1 shows the results of CPP measurement in Test 2 of Example 7. [Figure 13] 1 shows the measurement results of CPP in Test 3 of Example 7. [Figure 14] 1 shows the results of CPP measurement in Test 4 of Example 7. [Figure 15] 1 shows the experimental scheme design of Example 8. [Figure 16] 1 shows the measurement results of BS in test 1 of Example 8. A: Results of the movement distance of BS mice in test 1; B: Results of the movement distance of BS mice in test 2; C: Results of the movement distance of BS mice in test 3. [Figure 17] The effects of various polypeptides prepared in Example 9 on morphine-induced CPP in mice (n=12) are shown. ##: P<0.01 vs. saline group; **: P<0.01 vs. morphine group. [Figure 18] The results show that various polypeptides prepared in Example 9 have a negative effect on cocaine-induced behavioral sensitization in mice (n=10). *: P<0.05 vs. vehicle group; **: P<0.01 vs. vehicle group. [Figure 19]1 shows that various polypeptides prepared in Example 9 have a negative effect on alcohol-induced behavioral sensitization in mice (n=10). ##: P<0.01 vs. saline group; **: P<0.01 vs. alcohol group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] Currently, the issue of how to eliminate substance addiction or prevent relapse has attracted worldwide attention as a medical and social problem to avoid the enormous burden that substance addiction places on individuals, families and society. Interestingly, Liu et al. (Modulation of D2R-NR2B Interactions in Response to Cocaine, Neuron 52, 897-909, Decree 7, 2006) reported that the formation of a heteroreceptor complex between D2R and the NR2B subunit of the NMDA receptor was enhanced when dopamine was stimulated by cocaine in the neostriatum in vivo. In addition, Liu et al.'s investigation of the interaction between D2R and NR2B revealed that the region responsible for the formation of the D2R-NR2B complex is located in the third intracellular loop (IL3) of D2R. Further competition experiments by Liu et al. demonstrated that a motif containing 10 residues in IL3 (TKRSSRAFRA, T225-A234) is important for blocking binding between D2R and NR2B.
[0048] It should also be noted that Liu et al. tested various IL3 polypeptides derived from D2R and reported the following results (see Figures 3M and 3N in the above reference). That is, IL3 polypeptides derived from D2R inhibited the binding of D2R to NR2B only when they contained the above motif including T225-A234 (P1, P2, P3, and P5), and could not inhibit the binding of D2R to NR2B when the polypeptide did not have this motif (P4, I210-K226). In addition, the control peptide P6 obtained by scrambling the sequence of peptide P5 containing this motif also could not inhibit the binding of D2R to NR2B. Therefore, Liu et al. considered that the binding of D2R to NR2B may be sequence-specific and that TKRSSRAFRA may be the binding motif.
[0049] However, as a result of the inventors' research, contrary to the report by Liu et al., the inventors unexpectedly found that the polypeptide K211-T225 in the IL3 region of D2R (which, compared to polypeptide P4, which is thought not to be able to block the binding of D2R to NR2B, lacks one residue at the N-terminus and one residue at the C-terminus and does not contain the important motif TKRSSRAFRA) was able to reduce the interaction between D2R and NR2B.
[0050] The inventors further investigated and concluded that the polypeptide K211-T225 of the IL3 region of D2R and its variants with N- and C-terminal deletions can reverse the changes in addictive behavior in an addiction model.
[0051] Throughout this specification, unless otherwise specified, it is understood that the terms used herein have the meanings commonly used in the art.Therefore, unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which this invention belongs.In the event of any discrepancy, the description of this application shall prevail.
[0052] Hereinafter, the embodiments of the present invention will be described in more detail with reference to examples, and the advantages and various effects of the present invention will be more clearly described in the following examples. Those skilled in the art will understand that these specific embodiments and examples are intended to illustrate the present invention and do not limit the present invention. EXAMPLES
[0053] If specific conditions are not described in the examples, conventional conditions or conditions recommended by the manufacturer are followed, and if the manufacturer of the reagents or equipment used is not described, the reagents or equipment used are conventional commercially available products.
[0054] Unless otherwise stated, the experimental animals used in the examples were adult C57 / BL6J male mice (8 weeks old, weighing 25-30 g) purchased from Guangzhou Medical Laboratory Animal Center (China). The mice were housed under a 12-h light / 12-h dark cycle and had free access to food and water throughout the experimental procedure. All mice were acclimated in the animal room for 1 week before experimental manipulations.
[0055] In the examples, analysis of bands and morphological data was performed using ImageJ and Image Lab software (ImageJ 1.30), and statistical analysis was performed using GraphPad Prism 8 software. Sample amounts were selected according to previous reports (Arifin and Zahiruddin, 2017; Mead et al., 2012). All experiments were performed independently in triplicate. No randomization / blinding method was used. Data are presented as mean ± SEM. One-way or two-way ANOVA was performed for the various groups, with post-hoc testing by Tukey's multiple comparison test. p<0.05 was considered statistically significant. *: p<0.05, **: p<0.001, ***: p<0.0001 and ****: p<0.000001, unless otherwise stated.
[0056] Example 1. Confirmation of formation of D2R / NR2B complex in vivo Immunoprecipitation procedure: Protein samples (100–500 μg protein) from hippocampal tissue were used to perform co-immunoprecipitation. NR2B and D1R or D2R were precipitated using anti-NR2B and anti-D2R antibodies, D2R or NR2B, and 25 μl of Protein A / G PLUS-Agarose bead slurry (Santa Cruz Biotechnology, sc-2001), respectively.
[0057] Proteins were then separated on an 8% SDS-PAGE gel and detected with mouse anti-NR2B and mouse anti-D2R antibodies. Proteins were detected using HRP-conjugated secondary antibodies and enhanced chemiluminescence. Band density analysis was performed using Image Lab software.
[0058] To assess whether D2R and NR2B can form a protein complex, we first performed the co-immunoprecipitation assay described above to examine the possible interaction between D2R and NR2B in the hippocampus of normal mice, the results of which are shown in Figure 1.
[0059] As can be seen in Figure 1, NR2B could be precipitated from the hippocampal protein mixture by the D2R antibody, but not by the D1R antibody, indicating that the D2R and NR2B proteins bind to each other.
[0060] Example 2. Verification of the pathological significance of the D2R / NR2B complex Next, to examine whether the interaction state of D2R and NR2B is related to substance addiction, we performed immunoprecipitation experiments on hippocampal tissue samples obtained from mice with morphine-induced place preference (CPP) or behavioral sensitization (BS) induced according to the method described in Example 1. The results are shown in Figure 1.
[0061] As can be seen in Figure 1, the binding of D2R to NR2B was significantly increased in hippocampal tissue from both CPP and BS mice, confirming that the formation of the D2R / NR2B complex may play a role in the pathogenesis of substance addiction.
[0062] Example 3. Search for mutual binding sites in the D2R / NR2B complex To explore the physical interaction site between D2R and NR2B, we first obtained a cDNA fragment of the CT region (T428-C443) of D2R and a cDNA fragment of the third intracellular loop (IL3) region (K211-Q373) of D2R from the full-length D2R cDNA clone (Genbank accession number: M29066.1). These fragments were subcloned into the BamH1 / EcoR1 or BamH1 / Xho1 sites of pGEX-4T-3 plasmid (YouBio, Catalog No: VT1255). A methionine residue as the initiation codon and a stop codon were added as appropriate. All constructs were resequenced to confirm that the splicing fusion was properly performed. Each construct was expressed in live E. coli BL21 cells (AlpalifeBio, Catalog No.: KTSM104L) and the expressed proteins were purified from the bacterial lysate to obtain a GST fusion protein containing the IL3 region of D2R (GST-D2R-IL3) and a GST fusion protein containing the CT region of D2R (GST-D2R-CT). The specific locations of the coding sequence of the IL3 region and the coding sequence of the CT region on D2R are shown in Figure 2.
[0063] 500 μg of the dissolved hippocampal extract was diluted with 1× PBS / 0.1% Triton X-100 and incubated overnight at 4°C with 20 μl of GST resin for protein purification (TransGen Biotech, Catalog No: N21220, Beijing, China) saturated with GST protein alone or 20 μl of GST resin for protein purification saturated with 15 μg of the prepared GST fusion protein. The beads were washed 1 to 8 times with 1× PBS / 0.1% Triton X-100. The bound proteins were eluted with 2× loading buffer, separated by SDS-PAGE, and Western blotted with each antibody. The results are shown in Figure 3A.
[0064] As can be seen in Fig. 3A, NR2B was affinity precipitated by the IL3 domain of D2R, indicating that the IL3 domain of D2R is involved in the interaction.
[0065] Next, to further investigate the interaction sequences / sites between D2R and NR2B, the IL3 region was divided into the KVC region of D2R (K211-V270), the ES region of D2R (E271-S321), and the PQ region of D2R (P322-Q373). The specific locations of these regions on D2R are shown in Figure 2.
[0066] According to the method described in this Example, pull-down analysis was performed using a GST fusion protein containing the KVC region of D2R (GST-D2R-KVC), a GST fusion protein containing the ES region of D2R (GST-D2R-ES), or a GST fusion protein containing the PQ region of D2R (GST-D2R-PQ), and the results of Western blot analysis are shown in Figure 3B.
[0067] As can be seen in Fig. 3B , NR2B was affinity precipitated by the KVC region of D2R, indicating that the KVC region of D2R is involved in the interaction.
[0068] The KVC region was further divided into the KT region of D2R (K211-T225), the KL region of D2R (K226-L240), the KV region of D2R (K241-V255), and the IV region of D2R (I256-V270). The specific locations of these regions on D2R are shown in Figure 2.
[0069] According to the method described in this Example, pull-down analysis was performed using a GST fusion protein containing the KT region of D2R (GST-D2R-KT), a GST fusion protein containing the KL region of D2R (GST-D2R-KL), a GST fusion protein containing the KV region of D2R (GST-D2R-KV), or a GST fusion protein containing the IV region of D2R (GST-D2R-IV), and the results of Western blot are shown in Figure 3C.
[0070] Surprisingly, as shown in Figure 3C, the KL region of D2R (K226-L240) was unable to precipitate NR2B, but the KT region of D2R (K211-T225; hereafter, this region is referred to as the "KT polypeptide") affinity-precipitated NR2B.
[0071] Example 4. Inhibition of Complex Formation by Polypeptides in Vivo To verify the effect of the KT polypeptide of D2R on the D2R / NR2B complex in vivo, the C-terminus of the above region (K211-T225) was fused to the N-terminus of the transduction domain of the HIV-1 Tat protein (shown in SEQ ID NO:6; hereafter referred to as "TAT") to obtain a fusion protein capable of penetrating the blood-brain barrier. This fusion protein was named "TAT-D2R-KT".
[0072] CPP and BS mice were treated with TAT-D2R-KT, respectively, and mice treated with TAT alone served as controls (all mice were treated with a single intraperitoneal injection; 10 ml / kg body weight; drug concentration: 3 nmol / g). One hour after treatment, analysis was performed by co-immunoprecipitation as described in Example 1. The results are shown in FIG. 4.
[0073] As can be seen from FIG. 4, the KT polypeptide of the present invention competitively disrupted the D2R / NR2B interaction in the hippocampal tissues of CPP mice and BS mice.
[0074] Example 5. Blockade of morphine-induced CPP formation by polypeptides To evaluate whether the polypeptide of the present invention has an effect on morphine addiction, mice were treated with TAT-D2R-KT or TAT at the stage of formation of morphine-induced CPP, and the CPP score was measured.
[0075] The CPP equipment and test system are as follows: The CPP apparatus used in the experiments consisted of two boxes of equal volume (15 cm × 15 cm × 37 cm) with a movable door between them. Mice were free to move between the boxes during testing and were confined to one of the boxes during training. One box had a black interior and a striped floor, while the other box had a white interior and a checkered floor. All behavioral tests, including activity distance and activity time, were recorded by a camera and calculated using the SMART Video Tracking system (version 2.5; Panlab Technology for Bioresearch, Spain).
[0076] The experimental design is shown in Figure 5. On the first day, without any treatment, the mice were allowed to move freely between the two boxes for 15 min (before the test). On the second, fourth, sixth and eighth days, the control group (saline group) was administered saline (10 mL / kg) and the model group (morphine group) was administered morphine (10 mg / kg). The TAT group (3 nmol / g) and the TAT-D2R-KT group (3 nmol / g) were injected (intraperitoneally, 10 ml / kg body weight) 1 h before the morphine injection. After the injection, all mice were trained in the white box for 40 min. On the third, fifth, seventh and ninth days, all mice were administered saline and immediately placed in the black box for 40 min. On the tenth day, all mice were allowed to move freely between the two boxes for 15 min, the test was terminated, and the CPP scores (time spent by the mice) were shown in Figure 6.
[0077] As can be seen from FIG. 6, treatment with TAT-D2R-KT significantly reduced the CPP scores compared to subjects treated with TAT, indicating that TAT-D2R-KT can interfere with the formation of morphine-induced CPPs.
[0078] Example 6. Effect of polypeptides on the expression stage of morphine-induced CPP To further evaluate the specific effect of the polypeptide of the present invention on the expression stage of morphine-induced CPP, a test was carried out using the CPP device of Example 5 according to the experimental design shown in Figure 7. In this test, the model group (morphine group) was injected with saline on the 10th day, and the CPP mice in the TAT-D2R-KT group (morphine + TAT-D2R-KT) were treated with TAT-D2R-KT (single dose) on the 10th day, and the CPP score was measured 1 hour later. The experimental results are shown in Figure 8A.
[0079] As shown in FIG. 8A, treatment with TAT-D2R-KT on day 10 did not significantly reduce the CPP score.
[0080] However, when the CPP test was performed again on day 11, it was found that the CPP scores of the TAT-D2R-KT group on day 11 were significantly lower than those on day 10 (Figure 8B), suggesting that when the morphine addiction memory recurred on day 10, the memory associated with this memory was eliminated by TAT-D2R-KT.
[0081] Example 7. Elimination of morphine-induced drug relapse by polypeptides In order to verify that the polypeptide of the present invention can eliminate the memory associated with the relapse of the addictive memory, and to test the long-term effect of the polypeptide of the present invention on the drug relapse of morphine-induced CPP, we designed an experiment to induce natural withdrawal and drug relapse in CPP mice and carried out a number of tests, as shown in Figure 9. In these tests, a saline group was used as a control.
[0082] By administering morphine according to the conditions shown in Figure 9, we successfully induced CPP in mice on day 10. The results are shown in Figure 10.
[0083] The mice were then returned to their cages and kept for 3 weeks. On the 32nd day, the mice in the TAT and TAT-D2R-KT groups were treated with TAT or TAT-D2R-KT (3 nmol / g), respectively. One hour later, the mice were allowed to move freely for 15 minutes to perform test 1. The results are shown in Figure 11.
[0084] As can be seen from FIG. 11, the CPP scores of the mice in the TAT-D2R-KT group were significantly lower than those of the mice in the TAT group, indicating that the polypeptide of the present invention can eliminate environmentally induced drug relapse.
[0085] To further investigate the potential effect of the polypeptide of the present invention on drug relapse induced by addictive drugs, after test 1, each group was returned to its cage for 3 weeks, and on day 54, the TAT group and the TAT-D2R-KT group were injected with morphine (5 mg / kg). The mice were immediately placed in the experimental box and allowed to move freely for 15 minutes to perform test 2. The results are shown in FIG.
[0086] As can be seen from FIG. 12, in this test too, the CPP scores of the mice in the TAT-D2R-KT group were significantly lower than those of the mice in the TAT group.
[0087] To exclude dose effects, after test 2, each group was returned to its cage for 2 weeks, and on day 69, mice in the TAT and TAT-D2R-KT groups were injected with a high dose of morphine (15 mg / kg). Then, all mice were allowed to move freely for 15 minutes to perform test 3. The results are shown in Figure 13.
[0088] Surprisingly, administration of high doses of morphine was unable to reverse the significant reduction in CPP scores induced by TAT-D2R-KT, indicating that TAT-D2R-KT could eliminate drug relapse induced by low / high doses of addictive substances.
[0089] To further investigate the effect of TAT-D2R-KT on drug relapse induced by stress, each group was returned to its cage after test 3 and kept for one week. On the 77th day, yohimbine (α2 adrenergic receptor antagonist, 2 mg / kg, purchased from MCE, catalogue no. 18735) was administered to the mice in the TAT and TAT-D2R-KT groups, and a 15-minute test was performed after administration as test 4. The results are shown in FIG. 14.
[0090] As can be seen from FIG. 14, no significant difference was observed in the CPP scores between the TAT-D2R-KT group and the control group of mice, indicating that the polypeptide of the present invention was able to prevent stress-induced drug relapse.
[0091] Example 8. Verification of resistance to addiction-related behaviors using a behavioral sensitization model To further verify the effect of the polypeptide of the present invention on morphine addiction-related behavior, the above results were verified using a morphine-induced behaviorally sensitized mouse (BS) model.
[0092] The experiment was carried out according to the scheme shown in Figure 15. On the first day, all mice were acclimated to the experimental box for 1 h. Then, the mice were administered saline (control group) or 5 mg / kg morphine (TAT and TAT-D2R-KT groups) and placed in the experimental box (consisting of a white surface and a flat floor, measuring 50 cm × 50 cm × 35 cm). 3 The mice were placed in a box (Fig. 16A) and their locomotor activity was immediately recorded for 60 minutes. The effect of the drug was evaluated using the total walking distance of the mice as an index (hereinafter referred to as "Test 1"). The results are shown in Fig. 16A.
[0093] Then, all mice were returned to their cages and kept for one week. On the 9th day, TAT or TAT-D2R-KT (3 nmol / g) was administered to the mice, followed by morphine (1 mg / kg) one hour later, and all mice were placed in an experimental box to conduct a test to evaluate the effect of the drug (hereinafter referred to as "Test 2"). The results shown in Figure 16B showed that the locomotor activity of mice in the TAT-D2R-KT group for 60 minutes was significantly reduced.
[0094] After test 2, all mice were returned to their cages and reared for one week (withdrawal), and then returned to the experimental box for testing (hereinafter referred to as "test 3"). From the results shown in Figure 16C, it was found that the TAT-D2R-KT group still showed a significant decrease in locomotor activity even after one week of withdrawal, further indicating that the polypeptide of the present invention could eliminate morphine-induced drug relapse.
[0095] Example 9. Design and preparation of polypeptide variants As shown in detail in Table 1 below, based on the KT polypeptide (hereinafter referred to as "Pep1"), we designed and synthesized the following variants: N-terminal deleted variant Pep2, C-terminal deleted variant Pep3, variant Pep4 in which the middle segment RRR is mutated to GGG, and variant Pep5 in which the middle segment RKR is mutated to GGG.
[0096] [Table 1]
[0097] Next, the C-terminus of Pep1 to Pep5 was fused to the N-terminus of TAT to obtain fusion peptides capable of penetrating the blood-brain barrier.
[0098] Example 10. Examination of the effects of various polypeptides on morphine-induced CPP in mice Mice were administered morphine (1 mg / kg) or saline for 8 days, and then on the 10th day, various polypeptides (3 nmol / g) described in Example 9 were administered to the mice by intraperitoneal injection (10 ml / kg). Two days after administration, the expression of morphine-induced CPP was recorded according to the CPP experiment method in Example 5, and the results are shown in FIG.
[0099] As can be seen from Figure 17, Pep1 and the truncated forms Pep2 and Pep3 significantly reduced the activity distance of morphine-CPP mice, whereas Pep4 and Pep5, which have substituted middle segments, were unable to significantly reduce the activity distance, suggesting that the important motif of the polypeptide of the present invention is present in the middle segment of Pep1.
[0100] Example 11. Examination of the effects of various polypeptides on cocaine-induced BS in mice In order to verify that the polypeptide of the present invention is also effective against cocaine-induced addiction, the following test was carried out.
[0101] Cocaine (15 mg / kg) or saline was administered to the mice, and the test was performed for 30 minutes, and this was repeated for 5 days, followed by a 5-day rest period. On the 6th day of the rest period, the mice were given various polypeptides (3 nmol / g) as described in Example 9 by intraperitoneal injection (10 ml / kg) 1 hour before cocaine administration to induce the drug and perform the test. The results are shown in FIG. 18.
[0102] As can be seen from FIG. 18, as expected, Pep1 and the truncated forms Pep2 and Pep3 significantly suppressed the expression of sensitized behavior, whereas Pep4 and Pep5, which had a replacement in the middle segment, failed to suppress the expression of sensitized behavior.
[0103] Example 12. Examination of the effects of various polypeptides on alcohol-induced BS in mice In order to verify that the polypeptide of the present invention is also effective against alcohol-induced addiction, the following test was carried out.
[0104] During the training period, mice were administered alcohol (2.2 g / kg) or saline every other day, followed immediately by a 15-minute test, and this training was performed for 10 days. On the third day after training, the mice were administered various polypeptides (3 nmol / g) described in Example 9 by intraperitoneal injection (10 ml / kg) one hour before alcohol administration to induce drug induction, and then the test was performed. The results are shown in FIG. 19.
[0105] As can be seen from FIG. 19, as expected, Pep1 and the truncated forms Pep2 and Pep3 significantly suppressed the expression of sensitized behavior, whereas Pep4 and Pep5, which had a replacement in the middle segment, failed to suppress the expression of sensitized behavior.
Claims
1. Use of a polypeptide in the preparation of a medicament for the treatment and / or prevention of substance addiction, said polypeptide consisting of at least 11 consecutive amino acid residues of the sequence shown in SEQ ID NO:1 and comprising the sequence shown in SEQ ID NO:
2.
2. Use of a polypeptide in the preparation of a medicament for the treatment and / or prevention of relapse to a substance addiction, said polypeptide consisting of at least 11 consecutive amino acid residues of the sequence shown in SEQ ID NO:1 and comprising the sequence shown in SEQ ID NO:
2.
3. The use according to claim 2, wherein the relapse is caused by environmental factors, addictive substance factors or stress factors.
4. The use according to any one of claims 1 to 3, wherein the amino acid sequence of the polypeptide is selected from the sequence shown in SEQ ID NO:1, the sequence shown in SEQ ID NO:3 and the sequence shown in SEQ ID NO:
4.
5. The use according to any one of claims 1 to 4, wherein the addiction is induced by one or more substances selected from the group consisting of morphine, nicotine, alcohol, cocaine, codeine, dihydrocodeine, hydromorphone, oxycodone, methadone, morphine, fentanyl and pethidine.
6. Use of a nucleic acid molecule encoding a polypeptide according to any one of claims 1 to 5 in the preparation of a medicinal product for the treatment and / or prevention of substance addiction or its relapse.
7. 10. Use of an expression vector comprising a nucleic acid molecule according to claim 6 in the preparation of a medicament for the treatment and / or prevention of substance addiction or its relapse.
8. 8. Use of a host cell comprising a nucleic acid molecule according to claim 6 or an expression vector according to claim 7 in the preparation of a medicament for the treatment and / or prevention of substance addiction or its relapse.
9. A complex comprising the polypeptide according to any one of claims 1 to 5 and a carrier bound to the polypeptide for penetrating the blood-brain barrier, wherein the carrier for penetrating the blood-brain barrier is selected from the group consisting of HIV-1 Tat protein, insulin, cationized albumin, a monoclonal antibody against the rat transferrin receptor, a mouse-derived monoclonal antibody against the human insulin receptor, Penetratin, a transduction domain of the Tat protein, Pep-1 peptide, S4 13 -PV, Magainin 2 and Buforin 2.
10. A polypeptide consisting of 11 to 14 consecutive amino acid residues of the sequence shown in SEQ ID NO:1 and comprising the sequence shown in SEQ ID NO:2.
Citation Information
Patent Citations
Compositions and Methods For Modulating Dopamine Nerutransmission
US20080213271A1
Dopamine d2 receptor-disc1 interaction, compositions and methods for modulating same
US20120093822A1
